Baclofen for Gastroesophageal Reflux: Selective Use in Specific Phenotypes
Baclofen should be used selectively as adjunctive therapy for GERD patients with regurgitation-predominant or belch-predominant symptoms who have failed standard PPI therapy, but it is not recommended as routine primary or adjunctive therapy due to its challenging side effect profile. 1, 2
Evidence-Based Recommendations
When to Consider Baclofen
The 2022 AGA Clinical Practice Update provides clear guidance: personalize adjunctive pharmacotherapy to the GERD phenotype rather than using empiric treatment. Specifically, baclofen is indicated for:
- Regurgitation-predominant symptoms 1
- Belch-predominant symptoms 1
- Patients with proven GERD on objective testing who remain symptomatic despite PPI therapy 1
Research supports this phenotype-specific approach, showing baclofen significantly reduces belching (P = 0.038) and regurgitation (P = 0.036) 3, and is particularly effective in patients with predominantly upright reflux 3.
When NOT to Use Baclofen
Baclofen is not routinely recommended as primary or adjunctive therapy for extraesophageal reflux (EER) symptoms due to its challenging side effect profile 2. This is critical because:
- The FDA has not approved baclofen for GERD treatment; it is only indicated for spasticity from multiple sclerosis and spinal cord conditions 4
- Side effects (drowsiness, dizziness) limit tolerability 2, 5
- Long-term use increases adverse event incidence 6
Mechanism and Efficacy
Baclofen works as a GABA-B receptor agonist that:
- Reduces transient lower esophageal sphincter relaxations (TLESRs) 7, 8, 3
- Decreases both acid and non-acid reflux episodes 8
- Increases LES pressure 3, 9
Meta-analysis data confirms efficacy as add-on therapy: When combined with PPIs in refractory GERD, baclofen improves GERD-Q scores (SMD = -0.78), reduces non-acidic reflux episodes (SMD = -0.93), and improves DeMeester scores (SMD = -0.82) 6. However, it does not significantly reduce acid reflux episodes 6.
Clinical Algorithm for Use
Confirm GERD diagnosis with objective testing (endoscopy and/or prolonged wireless pH monitoring off PPI) 1
Optimize PPI therapy first - ensure adequate dosing (up to twice daily) and compliance 1
Phenotype the patient's symptoms:
Dosing: Studies used 40 mg orally 8, 3, 9, though specific dosing for GERD is not FDA-approved
Monitor closely for drowsiness and dizziness, which are the most common side effects 5
Critical Caveats
Abrupt withdrawal risk: The FDA label warns that hallucinations and seizures can occur with abrupt baclofen discontinuation - doses must be tapered slowly 4
Pregnancy concerns: Baclofen increases omphaloceles in animal studies and causes neonatal withdrawal symptoms. If used during pregnancy, gradually taper before delivery 4
Renal impairment: Dose reduction necessary as baclofen is renally excreted 4
Limited long-term data: Most studies evaluated short-term use (2 days to 2 weeks) 5, 3. The 2024 meta-analysis notes that long-term use increases side effects 6.
Practical Considerations
While baclofen reduces reflux episodes mechanistically, it may not provide clinical benefit in typical GERD because it also reduces secondary peristalsis and heightens esophageal sensitivity 10. This explains why it shows benefit in conditions like rumination and supragastric belching (where reducing TLESRs is therapeutic) but has never established a clear role in standard GERD treatment 10.
The bottom line: Reserve baclofen for the specific phenotype of regurgitation/belch-predominant refractory GERD after confirming diagnosis objectively and optimizing standard therapy. Do not use it as first-line therapy or routinely for extraesophageal symptoms.